2013 Predictions

Quote
Anonymous said:
No, a FDE should finish their contract and leave. You weren't promised a job, you were brought on for a short term need. You spent the last few months interviewing outside and now think you are entitled to a position that a long term rep in good standing should be getting. Makes no sense.
Click to expand...

Yes, I do feel entitled to be able to interview for that position. Feel free to interview against me and let the better candidate win! What a novel concept.
 




Anonymous said:
Here's some insight- anyone can post for those open diabetes positions- managers need to start having honest conversations with ALL their people, especially top talent who they want to retain ( not in their current role) but for any stable job with the company. If they have a good idea that the current reps territory will not be a sustainable one( whether it's due the the geography/ access/ portfolio) they need to encourage them to look at other attractive positions- this includes open men's health, diabetes, oncology. The NS/ MSK/ Cardio are all at risk and those managers who have any leadership skills should be strong enough "coaches" to have those talks- go where the pipeline is healthy and read, read, read what the investors- not what you are hearing from LLY news!! Educate yourselves from many avenues while you sit in offices-
Click to expand...

I'm sorry, you lost me at "managers need to start having honest conversations". I can't recall the last time my manager had one of those conversations...wait, it's because my manager doesn't believe in that. It might actually motivate our team.
 




Anonymous said:
disagree. the managers who put people first do, and are having those tough conversations with their people. they would rather deal with a vacant territory( especially since we are on team goals), then see someone lose a job which we all know is coming. for those who have integrity- they know what the future looks like/ which territories are high risk( metro ones especially). if your DSM won't paint a truthful picture, grab a peer who you feel has a good feel of the climate and talk it they with them. remember what happened to the ABS-NS reps who stayed because they wanted to ride it out!? the smart ones went over to men's health or diabetes. the others were displaced and left very soon after.
Click to expand...

The problem is most managers are not having these conversations. When we asked our manager exactly what was going on, he stated that we shouldn't believe the hype/rumors going around and that we are going to be fine.

Yep, this is the person who is "supposed" to have our best interest and is incharge of our promotions.... Sigh
 




Anonymous said:
The problem is most managers are not having these conversations. When we asked our manager exactly what was going on, he stated that we shouldn't believe the hype/rumors going around and that we are going to be fine.

Yep, this is the person who is "supposed" to have our best interest and is incharge of our promotions.... Sigh
Click to expand...

You must be in the biomedicine division (neuroscience) they have been told time and time again that everyone will have a job. I beg to differ!
 




Anonymous said:
Here's some insight- anyone can post for those open diabetes positions- managers need to start having honest conversations with ALL their people, especially top talent who they want to retain ( not in their current role) but for any stable job with the company. If they have a good idea that the current reps territory will not be a sustainable one( whether it's due the the geography/ access/ portfolio) they need to encourage them to look at other attractive positions- this includes open men's health, diabetes, oncology. The NS/ MSK/ Cardio are all at risk and those managers who have any leadership skills should be strong enough "coaches" to have those talks- go where the pipeline is healthy and read, read, read what the investors- not what you are hearing from LLY news!! Educate yourselves from many avenues while you sit in offices-
Click to expand...

I completely agree! I checked out our pipeline for Solanezumab ( http://clinicaltrials.gov/ct2/show/NCT01127633?term=solanezumab&rank=4 ), all but 2 trials have been completed. What I found interesting was that the Expedition Study in regards to Continued Safety Monitoring Study :

Start Date: December 2010
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)

There was so much press with this drug, but we probably won't have it FDA approved until 2016 if at all. With patents of Cymbalta and Evista expiring this year, we are going to keep tons of reps on board to sell Cialis, Axiron, Effient and Livalo??
 




Anonymous said:
I completely agree! I checked out our pipeline for Solanezumab ( http://clinicaltrials.gov/ct2/show/NCT01127633?term=solanezumab&rank=4 ), all but 2 trials have been completed. What I found interesting was that the Expedition Study in regards to Continued Safety Monitoring Study :

Start Date: December 2010
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)

There was so much press with this drug, but we probably won't have it FDA approved until 2016 if at all. With patents of Cymbalta and Evista expiring this year, we are going to keep tons of reps on board to sell Cialis, Axiron, Effient and Livalo??
Click to expand...



MSK Specialty reps just promoting Cymbalta? What are your honest " leaders" telling you about job security after 12/30/13??? Thought so.... Or Psych reps- with nothing to sell other than Strattera which is down to a 4% share... What will you be doing? Promises and NOT so promising. Look at what GSK, Pfizer all have done- major cuts and job loss- but at least they were clear with timelines. I like the " respect for people" tag lines. Nice....
 
















Six sigma will do an analysis that saYs we could save 400 million annuaLLY if we cancel the contract with Aramark and make low successful and unacceptable employees serve sub sandwiches and fried fare in the cafeterias. The price tag goes up to 404 million, if we discontinue the provision of Kuerig machines in favor of the new cheaper Mr. coffee version that requires a new water fill up with every cup.
 




Anonymous said:
If NS/MSK/Cardio will possibly be combining and FTE may be reallocated...why in the Hell are FDE from these divisions being placed in Diabetes openings? Complete slap in the face!!!
Click to expand...

Based on what? Spoken like a true, mediocre, long term, home by 3 PM, FTE.

Some FDE's are kicking the FTE butts. The smart managers are poaching the best FDE's to fill ranks with reps the customers know.

FTE's are not entitled to a job if someone else can do it better.

FYI, the FDE's are working "full time".

Just Sayin!!
 
















Anonymous said:
You must be in the biomedicine division (neuroscience) they have been told time and time again that everyone will have a job. I beg to differ!
Click to expand...

Yes, I am...

It is insulting to be told that everyone will have a job when the fact that we have Cymbalta that accounts for the majority of our portfolio and helps balance out Axiron will expire in December 2013, 3 sleeves selling Cialis (Neuro, MSK, Cardio), Axiron being the "little engine that couldn't", MSK Specialty reps only selling Cymbalta, Psych reps selling only one product(Strattera) and no mention of us selling anything in the future. Long before the Zyprexa expiration date, we were told not to worry because Lilly was doing everything it could to get us products to sell. One of the reasons for CVM scores. However, I haven't heard that enthusiasm of getting other drugs to sell in awhile.

We preach transperancy and it couldn't be more transperant that we are getting screwed.
 








Anonymous said:
Yes, I am...

It is insulting to be told that everyone will have a job when the fact that we have Cymbalta that accounts for the majority of our portfolio and helps balance out Axiron will expire in December 2013, 3 sleeves selling Cialis (Neuro, MSK, Cardio), Axiron being the "little engine that couldn't", MSK Specialty reps only selling Cymbalta, Psych reps selling only one product(Strattera) and no mention of us selling anything in the future. Long before the Zyprexa expiration date, we were told not to worry because Lilly was doing everything it could to get us products to sell. One of the reasons for CVM scores. However, I haven't heard that enthusiasm of getting other drugs to sell in awhile.

We preach transperancy and it couldn't be more transperant that we are getting screwed.
Click to expand...

Has anyone been told in biomedicines to "wait to hear from the higher ups" on any particular date when this will transpire?
 








I've heard managers in NS have been told to keep first week of April clear, no vacations...reading between the lines, this is when announcements start with everything in the new world going effective 6/1.
 








Top Bottom
Back
Quote